{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:39:07Z","timestamp":1786653547763,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    To evaluate the prognostic significance of prostate-specific antigen (PSA) decline depth and duration in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing abiraterone treatment. We retrospectively analyzed data from 153 high-risk patients with mHSPC receiving first-line abiraterone therapy. Patients were stratified based on PSA dynamics during treatment. Kaplan\u2013Meier survival analysis and Cox proportional hazards regression were used to assess the associations between PSA decline patterns, PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS). Among the 153 patients, 85 exhibited PSA nadir &lt;0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    , 48 had PSA nadir level ranging from 0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    to 4 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    , and 20 presented with a PSA nadir &gt;4 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    . During abiraterone treatment, PSA nadir &lt;0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    was significantly associated with improved median PSA-PFS (51.0 months vs 18.5 months vs 6.9 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001), median rPFS (52.0 months vs 24.3 months vs 10.3 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001), and median OS (not reached vs 48.5 months vs 28.1 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001) compared with PSA nadir \u22650.2 ng ml\n                    <jats:sup>-1<\/jats:sup>\n                    and &lt;4 ng ml\n                    <jats:sup>-1<\/jats:sup>\n                    , and PSA nadir \u22654 ng ml\n                    <jats:sup>-1<\/jats:sup>\n                    . In the cohort with PSA nadir &lt;0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    , achieving PSA &lt;0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    within 6 months and maintaining this level for over 10 months significantly enhanced clinical outcomes, as evidenced by median PSA-PFS (not reached vs 26.9 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001), median rPFS (not reached vs 27.5 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001), and median OS (not reached vs 44.4 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001). Cox regression analysis revealed that achieving PSA &lt;0.2 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    within 6 months post-treatment and sustaining this level for over 10 months are independent prognostic factors. In high-risk patients with mHSPC receiving first-line abiraterone, sustained PSA suppression is a key indicator of therapeutic response. The rate, depth, and duration of PSA decline are critical prognostic factors.\n                  <\/jats:p>","DOI":"10.4103\/aja202520","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:00:18Z","timestamp":1767884418000},"page":"304-309","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer"],"prefix":"10.4103","volume":"28","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Dong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Cheng","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"R1-20260430","first-page":"229","article-title":"Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer:association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"R3-20260430","first-page":"5","article-title":"[Analysis of epidemiology and advanced first-line endocrine therapy of prostate cancer","volume":"46","author":"Ma","year":"2008","journal-title":"Chin J Surg"},{"key":"R4-20260430","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R5-20260430","article-title":"Initial management approach for localized\/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care","author":"Conteduca","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE):an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy:post hoc analysis of phase 3 LATITUDE study","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.3390\/cancers15174392","article-title":"Prognostic role of dynamic changes in serological markers in metastatic hormone na\u00efve prostate cancer","volume":"15","author":"Roy","year":"2023","journal-title":"Cancers"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12885-021-08206-8","article-title":"Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer:a multicenter retrospective study","volume":"21","author":"Okamoto","year":"2021","journal-title":"BMC Cancer"},{"key":"R11-20260430","doi-asserted-by":"crossref","first-page":"100520","DOI":"10.1016\/j.medj.2024.09.009","article-title":"Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial","volume":"6","author":"Bian","year":"2024","journal-title":"Med"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.euo.2023.11.015","article-title":"Post hoc analysis of rapid and deep prostate-specific antigen decline and patient-reported health-related quality of life in SPARTAN and TITAN patients with advanced prostate cancer","volume":"7","author":"Small","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20260430","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer:updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R17-20260430","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1097\/JU.0000000000003257.01","article-title":"Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprivation therapy and docetaxel in arasens","volume":"209","author":"Saad","year":"2023","journal-title":"J Urol"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer:data from Southwest Oncology Group Trials 9346 (intergroup study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer:data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer:an exploratory analysis of the TITAN trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000277592","article-title":"Prognostic factors affecting progression and survival in metastatic prostate cancer","volume":"84","author":"Nayyar","year":"2010","journal-title":"Urol Int"},{"key":"R24-20260430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000334539","article-title":"Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer","volume":"88","author":"Divrik","year":"2012","journal-title":"Urol Int"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","article-title":"The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer:stratified analysis based on pain, prostate-specific antigen, and Gleason score","volume":"74","author":"Miller","year":"2018","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:13Z","timestamp":1786649953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202520","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}